dual IRAK1/4 inhibitors (Cincinnati Children's Hospital Medical Center)

N/A

Report date: 2025/03/19 11:37:38
NME

Base Information

Drug Namedual IRAK1/4 inhibitors (Cincinnati Children's Hospital Medical Center)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 1 antagonistsInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 1Interleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCincinnati Children'S Hospital Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCincinnati Children'S Hospital Medical Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A